Read the Full Report (Pdf)
Total Page:16
File Type:pdf, Size:1020Kb
Medicom International Conference Series in Rheumatology Check out the EULAR 2020 Medicom Podcast EULAR E-Congress 2020 European League Against Rheumatism 3-6 JUNE 2020 Virtual Congress PEER-REVIEWED CONFERENCE CONFERENCE REPORT Olokizumab shows axSpA: certolizumab pegol Fast onset of improvement significant improvements reduces acute anterior in PsA with upadacitinib in RA uveitis SELECT-PsA-1: upadacitinib showed Results from the phase 3 CREDO-1 The phase 4 C-VIEW trial showed fast improvements in musculoske- trial demonstrated that the novel significant reductions of AAU flare letal symptoms, psoriasis, physical IL-6 blocker olokizumab signifi- rate and axial spondyloarthritis function, pain, and fatigue and cantly improved disease activity disease activity with certolizumab inhibited radiographic progres- and physical function in rheuma- pegol treatment. sion of patients inadequately toid arthritis patients. responding to non-bDMARD. read more on PAGE 4 read more on PAGE 7 read more on PAGE 11 Editor Prof. Dennis McGongale, University of Leeds, United Kingdom Contents Letter from the Editor 3 Rheumatoid Arthritis 3 Low DAS at 4 months predicts sustained DMARD-free remission 4 Olokizumab significantly improves RA features and patient- reported outcomes COLOPHON 5 New nanoparticle promising future agent in RA 5 Immune-related AEs due to checkpoint inhibitors require care Editor Prof. Dennis McGonagle coordination University of Leeds, UK 6 Preliminary findings suggest rozibafusp alfa effective and Advisory Board Dr Agna Neto Hospital Central do Funchal, Madeira; tolerable in RA Chronic Diseases Research Center (CEDOC), 7 Ankylosing Spondylitis NOVA Medical School, Portugal 7 TNF-α inhibitors improve bone mineral density in AS patients Publishing Director Paul Willers 7 Certolizumab pegol reduces acute anterior uveitis in axial Editorial Manager Lisa Colson spondyloarthritis Editorial Coordinators Dr Joery Goossens 8 AxSpA real-life remission rates higher on biologics Sanne Lauriks Medical Writer Constance de Koning 9 Worse response axSpA patients to second TNFi versus first TNFi Production Manager Desiree Heijl 9 Reduced maintenance dose of certolizumab pegol can be used in Graphic Design MOOZ grafisch ontwerp axSpA Layout In het Houten Paard 10 Psoriasis and Psoriatic Arthritis ISSN 2468-8762 20:6 10 Secukinumab monotherapy as efficient as adalimumab All rights reserved. 11 Upadacitinib provides fast onset of improvement in psoriatic No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other arthritis electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical 13 Adalimumab added to methotrexate yields better results in PsA reviews and certain other noncommercial uses permitted by copyright law. than methotrexate escalation Copyright ©2020 Medicom Medische Uitgeverij BV 13 Ixekizumab shows sustained improvements in pain and fatigue at 3 years Disclaimer: Our independent peer-reviewed Medicom Conference Reports are made 14 Osteoporosis and Osteoarthritis possible by sponsoring. The ideas and opinions expressed in this journal or other associated publications do not necessarily reflect those of Medicom 14 Positive effect denosumab on fall risk Medical Publishers. Although great care has been taken in compiling the content of this publication, Medicom is not responsible or liable in 15 Hydroxychloroquine not effective in patients with hand any way for the currency of the information, for any errors, omissions or osteoarthritis inaccuracies in the original articles, or for any consequences arising from the content. Products mentioned in this report may not be covered by marketing authorisation in some countries. Product information, applicable 15 Higher mortality risk with tramadol versus NSAIDs for in your country, should be reviewed before prescribing. The mention of any osteoarthritis patients product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the 17 Systemic Sclerosis and Systemic Lupus Erythematosus treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages 17 Composite endpoint CRESS for primary Sjogren’s syndrome and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently 17 Wide variation in prescription and dosing patterns for provided by the manufacturer of each drug to be administered to verify hydroxychloroquine in SLE the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions 18 Subclinical myocardial involvement progresses in SSc patients about the features or limitations of any products. Medicom assumes no responsibility for any injury or damage to persons or property arising out of 19 Anifrolumab achieves rapid and durable BICLA-response or related to any use of the material contained in this publication or to any 20 COVID-19 errors or omissions. 20 COVID-19 and inflammatory rheumatic disease: some key issues Head Office Postal address Medicom Medical Publishers Medicom Medical Publishers Faas Eliaslaan 5 PO Box 90 3742 AR Baarn 3740 AB Baarn The Netherlands The Netherlands Join us on LinkedIn Telephone +31 85 4012 560 MEDI C AL PUBLI S H E R S E-mail [email protected] Letter from the Editor Dear Reader, I would like to welcome you to this summary of selected The Congress also devoted time to dealing with the abstracts from EULAR 2020 that captures some key impact of COVID-19 in subjects taking DMARDS and also findings that have immediate clinical relevance or exploring the impact of DMARDS on reducing severe that will pique the community interest for further inflammation linked to COVID-19 in non-rheumatology research towards improved patient care. This was the patients. The 2020 SARS-CoV2 pandemic with its first ever virtual EULAR Congress reflecting the impact high inflammation levels linking to mortality and the of the COVID-19 pandemic on the Global Rheumatology absence of effective anti-virals has culminated in a community. The Congress was due to take place in rheumatological type “geggenpress” where our legacy Frankfurt, which is a mere 45km from Mainz where drugs are at the forefront on strategies to contain this sports terminology such as “heavy metal football” and viral foe. “geggenpress”(counter press or on the front foot) have emanated and entered popular parlance. At the time of writing, corticosteroids have been the big winner in severe COVID-19 pneumonia. However, high- I thought that these terms also applied well to the EULAR dose steroids in rheumatology patients may be a risk 2020 Congress in the context of the current pandemic. factor for more severe COVID-19. There was one other Rheumatology certainly had shining past with the loser at EULAR 2020 and that was hydroxychloroquine Nobel Prize winning discovery of corticosteroids by where it failed to show efficacy in a clinical trial in OA, the Rheumatologist Philip Hench and colleagues but but the door was left open as there may have been an had entered relative obscurity. The COVID-19 pandemic impact on pain. This is not dissimilar to the failure of has shown Rheumatology now really is a “heavy metal” hydroxychloroquine in COVID-19 pneumonia, although speciality with numerous therapeutic agents to treat discussions lumbar on. The Rheumatology 2020 inflammatory arthritis with these being repurposed therapeutic geggenpress against COVID-19 is still very and evaluated at the forefront of the COVID-19 battle. much in play. However, the EULAR e-congress appears We now have a large squad of drugs and continue to to have been a great success and we, like Mr Klopp, acquire drug classes with several examples of these the father of heavy metal football and geggenpressing, contained in the selected abstracts herein, such as should take great solace from our achievements that the emergence of JAK inhibition as utility players in have also taken place behind closed doors in 2020. inflammatory arthritis and also covers aspects such as specialised drug players with more highly adapted Sincerely, roles in seronegative inflammatory arthritis and lupus. Prof. Dennis McGonagle Biography Dennis McGonagle, FRCPI, PhD, is an Academic Rheumatologist at the University of Leeds and section head of Experimental Rheumatology. He graduated in Medicine from the University College Dublin in 1990 and undertook postgraduate training in Dublin and Leeds where he completed his PhD. He has developed the modern enthesitis model for spondyloarthropathies and psoriatic arthritis including the cytokine mediated enthesis originating theory of disease (Lancet 1998). He also described the synovioentheseal complex, nail anchorage to the skeleton, developed an integrated biomechanical and immunology model for PsA, and a mechanistic disease classification of immune diseases (PLoS Med 2006). His group also discovered synovial fluid mesenchymal stem cells, which is being researched towards osteoarthritis therapy development. Prof. McGonagle has also served on the EULAR scientific committee and is a Prof. Dennis McGonagle member of the Editorial Board of ARD. Conflict of Interest Statement: Prof. McGonagle has undertaken research and/or educational programme